Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060801 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT00060801: Clinical Trial Phase 2 study, sponsored by Boehringer Ingelheim.
NCT00060801 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 420 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060801, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of 24 weeks of treatment with BIIL 284 BS compared with placebo on pulmonary function and incidence of pulmonary exacerbation in adult and pediatric cystic fibrosis patients.
Interventions
- DRUG BIIL 283 BS (Amelubent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2003-05 |
| Phase | Phase 2 |
Why NCT00060801 stopped before completion
NCT00060801 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher).
The record links to 0 conditions, and to 1 intervention - of which BIIL 283 BS (Amelubent) is the first listed.
NCT00060801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060801 about?
NCT00060801 is a clinical study titled "Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients". The purpose of this study is to determine the effect of 24 weeks of treatment with BIIL 284 BS compared with placebo on pulmonary function and incidence of pulmonary exacerbation in adult and pediatric cystic fibrosis patients.
What is the current status of trial NCT00060801?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00060801?
The interventions under investigation include: BIIL 283 BS (Amelubent) (DRUG).
Who is sponsoring clinical trial NCT00060801?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00060801's enrollment target sits among peer trials
420 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia